Form 4: Pediatrix Director Sylvia Young Receives Equity Grant
Statement of Changes in Beneficial Ownership
Director Sylvia Jean Young was granted 7,196 restricted shares of Pediatrix Medical Group, Inc. as part of an annual equity award.
Summary
- Director Sylvia Jean Young acquired 7,196 shares of common stock in Pediatrix Medical Group, Inc. (MD).
- The shares were granted as restricted stock under the company's Amended and Restated 2008 Incentive Compensation Plan.
- The transaction occurred on May 7, 2026, with a grant price of $0 per share.
- Following this transaction, the director's total beneficial ownership increased to 47,814 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
- Standard annual equity grant process indicates stable corporate governance practices.
Negatives
- None identified; this is a routine compensatory disclosure.
Risks
- Market volatility affecting the future value of the granted restricted stock.
- Vesting conditions require the director to remain with the company until May 7, 2027, to realize the full benefit.
Future Outlook
The restricted shares are scheduled to vest on May 7, 2027, subject to the terms of the 2008 Incentive Compensation Plan.
Management Comments
- The filing notes that the shares were granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan.
Industry Context
StockSavvy.ai notes that routine equity grants to board members are standard industry practice for public healthcare companies to ensure long-term alignment with shareholder value.
Comparison to Industry Standards
- The grant structure is consistent with standard executive and director compensation packages seen in the healthcare services sector.
- The use of restricted stock units (RSUs) is a common retention and incentive tool used by peers such as HCA Healthcare and Tenet Healthcare.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Director Sylvia J. Young appointed Mary Ann E. Moore and Tara McManus as attorneys-in-fact for SEC filings. | 2025-10-28 | Standard administrative update to facilitate regulatory compliance. |
Stakeholder Impact
- Minimal impact on shareholders as this is a standard compensatory award.
Next Steps
- Vesting of the 7,196 restricted shares on May 7, 2027.
Key Dates
| Date | Description |
|---|---|
| 2025-10-28 | Date of Power of Attorney execution. |
| 2026-05-07 | Date of transaction and grant of restricted shares. |
| 2027-05-07 | Vesting date for the granted restricted shares. |
Keywords
Pediatrix Medical Group, MD, Form 4, Insider Trading, Equity Compensation, Director Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.